These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Inflammation as a Therapeutic Target in Atherosclerosis. Nguyen MT; Fernando S; Schwarz N; Tan JT; Bursill CA; Psaltis PJ J Clin Med; 2019 Jul; 8(8):. PubMed ID: 31357404 [TBL] [Abstract][Full Text] [Related]
49. Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes. Alam M; Kontopantelis E; Mamas MA; Savinova OV; Jhaveri A; Siddiqui E; Jhamnani S Coron Artery Dis; 2023 May; 34(3):210-215. PubMed ID: 36762630 [TBL] [Abstract][Full Text] [Related]
50. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents? Ridker PM Circulation; 2020 Mar; 141(10):787-789. PubMed ID: 32150469 [No Abstract] [Full Text] [Related]
51. Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach. Mikkelsen RR; Hundahl MP; Torp CK; Rodríguez-Carrio J; Kjolby M; Bruun JM; Kragstrup TW Eur J Pharmacol; 2022 Jun; 925():174998. PubMed ID: 35533739 [TBL] [Abstract][Full Text] [Related]
52. Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. Wong CC; Baum J; Silvestro A; Beste MT; Bharani-Dharan B; Xu S; Wang YA; Wang X; Prescott MF; Krajkovich L; Dugan M; Ridker PM; Martin AM; Svensson EC Cancer Res; 2020 Dec; 80(24):5597-5605. PubMed ID: 33023946 [TBL] [Abstract][Full Text] [Related]
53. The Role of Colchicine in Acute Coronary Syndromes. Vaidya K; Martínez G; Patel S Clin Ther; 2019 Jan; 41(1):11-20. PubMed ID: 30185392 [TBL] [Abstract][Full Text] [Related]
54. Effect of canakinumab on frailty: A post hoc analysis of the CANTOS trial. Orkaby AR; Thomson A; MacFadyen J; Besdine R; Forman DE; Travison TG; Ridker PM Aging Cell; 2024 Jan; 23(1):e14029. PubMed ID: 37927208 [TBL] [Abstract][Full Text] [Related]
55. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. Ridker PM J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883 [TBL] [Abstract][Full Text] [Related]
56. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes? Ruscica M; Ferri N; Macchi C; Corsini A; Sirtori CR Ann Med; 2018 Sep; 50(6):461-484. PubMed ID: 29976096 [TBL] [Abstract][Full Text] [Related]
57. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Thuren T; Zalewski A; Libby P Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649 [TBL] [Abstract][Full Text] [Related]
58. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Ridker PM; MacFadyen JG; Thuren T; Libby P Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417 [TBL] [Abstract][Full Text] [Related]
60. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. Sun M; Dubé MP; Hennessy T; Schultz CJ; Barhdadi A; Rhainds D; Hillis GS; Tardif JC Int J Cardiol; 2022 Sep; 363():20-22. PubMed ID: 35716932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]